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Available online 3 September 2016There has recently been a resurgence of interest in psychedelics, substances that profoundly alter perception and
cognition and have recently demonstrated therapeutic efﬁcacy to treat anxiety, depression, and addiction in the
clinic. The receptormechanisms that drive theirmolecular and behavioral effects involve activation of cortical se-
rotonin 5-HT2A receptors, but the responses of speciﬁc cellular populations remain unknown. Here, we provide
evidence that a small subset of 5-HT2A-expressing excitatory neurons is directly activated by psychedelics and
subsequently recruits other select cell types including subpopulations of inhibitory somatostatin and
parvalbumin GABAergic interneurons, aswell as astrocytes, to produce distinct and regional responses. To gather
data regarding the response of speciﬁc neuronal populations, we developed methodology for ﬂuorescence-acti-
vated cell sorting (FACS) to segregate and enrich speciﬁc cellular subtypes in the brain. These methods allow for
robust neuronal sorting based on cytoplasmic epitopes followed by downstreamnucleic acid analysis, expanding
the utility of FACS in neuroscience research.













Classic serotonergic hallucinogens, also called psychedelics, produce
profound cognitive and perceptual alterations in humans. Recently,
there has been a resurgence of interest in the clinical study of psyche-
delics, and remarkable efﬁcacy has been demonstrated in clinical trials
for various psychiatric conditions such as anxiety (Gasser et al., 2014;
Grob et al., 2011) and addiction (Bogenschutz et al., 2015; Johnson et
al., 2014). A greater knowledge of the molecular mechanisms of action
of psychedelics has the potential for further understanding of normal
cognitive and perceptual behaviors, as well as several psychiatric disor-
ders. Psychedelics are a class of drug that includes several distinct chem-
ical structures. Although many psychedelics exhibit complex receptor
pharmacology (Halberstadt and Geyer, 2011; Nichols, 2016), all are be-
lieved to exhibit their primary effects through activation of the brain se-
rotonin 5-HT2A receptor (Glennon et al., 1984; Halberstadt, 2015) in
both humans (Vollenweider et al., 1998) and rodents (Gresch et al.,
2007).
Serotonin 5-HT2A receptormRNA and protein are expressed inmany
brain regions, particularly the neocortex, but also in the claustrum,macology and Experimental
t., New Orleans, LA, 70112, USA.
. This is an open access article undermammillary nucleus, amygdala, and striatum (Pasqualetti et al., 1996;
Pazos et al., 1985; Weber and Andrade, 2010). Extensive work in ro-
dents indicates that the cortex is a critical locus for their behavioral ef-
fects (Gonzalez-Maeso et al., 2007; Gresch et al., 2007). In humans,
psychedelics can lead to increased [18F]-ﬂuorodeoxyglucose uptake
(Vollenweider et al., 1997), decreased blood ﬂow and blood oxygen
level dependent (BOLD) signal (Carhart-Harris et al., 2012), and disrup-
tion of oscillations in several cortical regions (Riba et al., 2004;
Muthukumaraswamy et al., 2013).
Activation of 5-HT2A receptors in the cortex is necessary for the ef-
fects of psychedelics, but the role of individual cell types remains un-
known. For example, systemic administration of psychedelics
produces widespread gene expression changes in the prefrontal cortex
(PFC) (Nichols et al., 2003; Nichols and Sanders-Bush, 2002) and so-
matosensory cortex (SSC) (Gonzalez-Maeso et al., 2003), but these
data refer only to entire structures and not to their cellular constituents.
Interestingly, a subset of deep pyramidal cells in layer V of the prefrontal
cortex is directly depolarized by 5-HT2A receptor activation in brain
slices, implicating an intracortical mechanism in the action of psyche-
delics (Beique et al., 2007). It is also known that DOI causes GABA re-
lease and increases of cFos within Gad67-expressing cells in the PFC
and orbital cortex (Abi-Saab et al., 1999; Wischhof and Koch, 2012),
but the identity of the type of interneurons activated is unknown. Few
studies have examined the activation of non-neuronal cells in thethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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dendrocytes of the PFC following LSD (Reissig et al., 2008). Understand-
ing how individual cells within a particular cortical region respond to
psychedelics and interact with each other will be crucial to understand
fully theirmechanismof action and for developing potential therapeutic
applications.
Here, we demonstrate that psychedelics activate heterogeneous
populations of cells in the medial PFC (mPFC) and SSC, including excit-
atory neurons, inhibitory neurons, and astrocytes. We show that imme-
diate early gene inductionwithin activated cells varieswith brain region
and cell type, and that a subset of 5-HT2A-expressing neurons is activat-
ed by psychedelics and internalizes receptors following drug adminis-
tration in several areas, including the mPFC, SSC, and claustrum. Our
results support the hypothesis that a group of excitatory neurons is di-
rectly activated by psychedelics, and that other cell types, including so-
matostatin and parvalbumin interneurons, are subsequently recruited.
Signiﬁcantly, to gather our data we developed methodology that al-
lows robust sorting and puriﬁcation of cells by FACS utilizing cytoplas-
mic and extracellular membrane epitopes. For example, these
techniques allowed us to segregate and purify large populations of so-
matostatin and parvalbumin GABAergic interneurons using non-nucle-
armarkers. The ability to sort and purify large cellular populations from
whole brain tissues using non-nuclear markers signiﬁcantly expands
the utility of ‘neurocytometry’ – a term for the analysis of brain cells
with ﬂow cytometry. Overall, neurocytometry ismore rapid and cost ef-
fective than existingmethods of sorting whole brain cells such as single
cell laser capture.
2. Methods
2.1. Animals, Drugs, and Treatment
Male Sprague-Dawley rats obtained from Harlan (Indianapolis, IN)
were between 250 and 300 g upon arrival, and between 300 and
350 g during treatment. Animals were housed individually for at least
seven days before treatment, during which time they were handled
for 10 min each day. Rats were individually housed in translucent
home cages, allowed free access to food and water, and kept on a
12:12 h light/dark cycle. Rats were injected (i.p.) with either sterile sa-
line or (R)-DOI·HCl (6.0mg/kg) during their dark cycle, and placed back
into their home cage for 105 min. Following this interval, the rats were
brieﬂy anesthetized with isoﬂurane and decapitated. Rats were proc-
essed in pairs on each day of experimentation; one control and one
drug-treated animalwere always processed together in parallel. The en-
tire brain was dissected within 3min, and either frozen in 2-methyl bu-
tane cooled with dry ice for 20 s (prior to Method A), or cut into 2 mm
coronal sections and immediately submerged into ice-cold, freshly pre-
pared 4% paraformaldehyde in PBS (prior to Method B). Frozen brains
were stored at−80 °C until further processing. (R)-DOI·HCl was syn-
thesized in the laboratory of Dr. D.E. Nichols at Purdue University. Ani-
mals used in these studies were maintained in accordance with the
U.S. Public Health Service Policy on Humane Care and Use of Laboratory
Animals, and all protocols were approved by the Institutional Animal
Care and Use Committees of LSUHSC.
2.2. Brain Dissection and Neuronal Dissociation (Method A)
These dissociation and FACS procedures were adapted, withmodiﬁ-
cations, from theHope Laboratory at NIDA (Guez-Barber et al., 2012; Liu
et al., 2014). Frozen brains were sliced into 1mm thick coronal sections
from +3.7 mm to +2.7 mm, +2.7 mm to +1.7 mm and +1.7 to
+0.7 mm, relative to bregma. Razors were used to dissect the frozen
mPFC from the two anterior slices and the SSC from the posterior
slice. The tissue was kept chilled on ice for all of the remaining proce-
dures. Frozen brain tissue was covered in several drops of Hibernate-A
(Brain-Bits) neuronal media to thaw on a cold glass plate. The brainregions were minced in Hibernate-A with razors 200 times in orthogo-
nal directions until amushy consistencywas achieved. The solutionwas
then pipetted into a chilled microfuge tube (Protein LoBind 1.5 ml,
Eppendorf), in which Hibernate-A was added to a total volume of
600 μl. The solution was allowed to settle for 5 min. The supernatant
was transferred into another tube and an additional 500 μl of Hibernate
Awas added to the sample. This solutionwas pipetted back and forth 15
times through a ﬁre-polished glass Pasteur pipette with a tip diameter
of ~0.6 mm. After 5 min, the supernatant containing additional dissoci-
ated cells was combined with the initial supernatant. The dissociated
cells (~1 ml) were ﬁltered sequentially through pre-wetted 100 μm
and 40 μm ﬁlters and stained.
2.3. Neuronal Soma Fixation and Dissociation (Method B)
Fresh, 2mmcoronal sections immersionﬁxed in cold 4% paraformal-
dehyde for 10–12 h were transferred to PBS and washed 4× for 10 min
each. The mPFC (+3.7–+1.7 mm) and SSC (+1.7 to−0.7 mm) were
then dissected, as above, and placed into a cold solution of PBS supple-
mented with 0.1% Tween-20 (PBS-T). The brain sections were then
mincedwith sharp razors on an ice-cold glass plate for 5min. The tissue
was collected in PBS-T, and spun at 300 ×g for 5 min. The supernatant
was removed, and tissue was resuspended in 1 ml Accutase enzymatic
solution, and pushed back and forth 10× through a 1 ml syringe con-
nected to a 19 G needle. The tissue was incubated while shaking at
room temperature for 1 h. After removal of the enzyme and rinse with
cold PBS-T, the tissue was passed back and forth 10 times through a sy-
ringe coupled to a 21 G needle. After settling for 5 min, the supernatant
was removed and 500 μl of PBS-T was added to the tissue. The tritura-
tion cycle was completed sequentially with a 23 G needle and then
twice more with a 25 G needle. Following each set of 10 triturations,
the supernatant was collected after 5 min of settling. Trituration cycles
were completed on ice. After all trituration cycles were completed, the
supernatants were combined and ﬁltered through a 70 μmmesh ﬁlter
before staining.
2.4. FACS Antibody Staining
The ﬁltrate was transferred into low protein-binding 1.5 ml
microfuge tubes (Eppendorf) for antibody staining. Staining carried
out on unﬁxed cells (Method A) was performed with primary antibod-
ies pre-conjugated by the manufacturer to ﬂuorescent secondary anti-
bodies, including α-phospho-cFos-AlexaFluor647 (1:400, Cell
Signaling; RRID: AB_11178518). This antibody is directed against a syn-
thetic phosphopeptide corresponding to Ser32 of cFos. Phosphorylation
of cFos at this residue has been shown to result in increased stability and
nuclear localization of the protein (Sasaki et al., 2006). Other antibodies
were: α-NeuN-Phycoerythrin (1:800, Millipore; RRID: AB_11212465);
α-GFAP-AlexaFluor488 (1:500, BD Pharmingen; RRID: AB_1645350).
Cells were simultaneously incubated with 4′,6-diamidino-2-
phenylindole (DAPI) to stain nuclei at a ﬁnal concentration of 1.43 μM.
Incubationswere performed on a rotator at 4 °C for 90min in Hibernate
A.
Staining of ﬁxed neurons using Method B utilized the following pri-
mary antibodies: goat-α-somatostatin (1:200, Santa Cruz; RRID: AB_
2302603); rabbit-α-parvalbumin PV-25 (1:15,000, Swant; RRID: AB_
10000344); and mouse-α-cFos C-10 (1:300, Santa Cruz; RRID: AB_
10610067). Primary incubations were performed for 1.5 h shaking at
RT in PBSwith 0.1% Tween-20, supplementedwith 1000U/ml RNase in-
hibitor (RNAsin, Promega) and 1 mm dithiothreitol (DTT). Two washes
in cold PBS-T were followed by secondary incubations with the appro-
priate secondaries at 4 °C in PBS-T. All secondaries were highly cross
adsorbed and used at a concentration of (1:750): α-goat-647 (Jackson;
RRID: AB_2340437), α-mouse-488 (Jackson; RRID: AB_2338854), α-
rabbit-647 (Invitrogen; RRID: AB_2535813). DAPI (1.43 μm) was also
included in secondary incubations. Following secondary incubations,
264 D.A. Martin, C.D. Nichols / EBioMedicine 11 (2016) 262–277cells were washed two times and resuspended in 500 μl of PBS-T, con-
taining α-NeuN-Phycoerythrin (1:800, Millipore) for FACS. Stained
cells were transferred to 5 ml tubes for ﬂow cytometry and kept on
ice until cell sorting.All EventsA)
















































Photomicrographs of Sorted Cells
Fig. 1. FACS gating strategy:Data are from a representative sort ofmPFC; all runs produced sim
DAPI(+) gate includes cells and excludes debris. B) Forward and Side Scatter gates eliminate
Neun-PE(−) events represent non-neurons. D) NeuN-PE(−)/GFAP-488(+) events represent
(left middle), PE (right middle), and 488 (right) channels. Sorted neurons (top), non-neuro
markers in sorted cells, relative to gapdh expression. “***” & “ns” indicate p b 0.001 & non
astrocytes and non-neurons; N = 12, neurons).2.5. FACS
All samples were sorted on a BD FacsAria into empty 1.7 ml






















ilar patterns. Numbers represent percentages of cells within gates. A) All events are shown.
irregularly-shaped DAPI(+) events. C) NeuN-PE(+) events represent neurons, whereas
astrocytes. E) Appearance of representative sorted cells (63×) in brightﬁeld (left), DAPI
ns (middle), and astroctyes (bottom). G) Expression levels of cell-type-enriched mRNA
-signiﬁcant. One-way ANOVA, Tukey post-hoc performed between all groups (N = 6,
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phycoerythrin (PE) and AlexaFluor-488 ﬂuorophores was applied
based on the analysis of singly stained samples. 100,000 events from
each sample were analyzed to set gates prior to cell sorting. The gating
strategy for cell sorting following Method A is shown in Fig. 1. A popu-
lation of cell bodies, deﬁned as the events falling within a narrow
band of high DAPI ﬂuorescence and displaying clustered forward- and
side-scatter characteristics, comprised 4.4% (range 2.9–5.5%) of the
total events on average for each run; the remaining 95.6% (range
94.5–97.1%) of events was comprised of cellular debris and was exclud-
ed from further gating. A clear segregation between neuronal and non-
neuronal populationswas apparent based on NeuN-PE immunoreactiv-
ity (IR) and these populationswere veriﬁed by downstreamQPCR anal-
ysis (Fig. 1). A continuum of phospho-cFos-647 ﬂuorescence intensity
was observed within the PE(+) (neuronal) population, and the PE(+)
population was subdivided such that “Fos(+)” populations consist of
PE(+) neuronal events that were in the top ~2.5% of phospho-cFos-
647 emission intensity, and “Fos(−)” populations consist of the lowest
~80% of PE(+) neurons with respect to phospho-cFos-647 emission in-
tensity. During the course of each run, 2 non-neuronal populationswere
sorted, sequentially: 1) Non-neurons as all PE(−) events 2) Astrocytes
as PE(−)/GFAP-488(+) events. GFAP-488(+) events were deﬁned as
events in the top 15% of GFAP-488-emission intensity within the
PE(−) (Non-neuronal) group. Therefore, 4 populations were sorted:
1) Fos(+) neurons; 2) Fos(−) Neurons; 3) All Non-neurons; 4)
GFAP(+) Non-neurons. An aliquot of dissociated, but unsorted, cells/
debris from each sample was also frozen at−80 °C for QPCR analysis
of unsorted tissue.
The sorting strategy following Method B is illustrated in Figs. 8–9. A
population of neuronal somata, consisting of 11.3% (range 9.5–13.5%) of
total events, was found to display a single, narrow peak of DAPI ﬂuores-
cence. Neurons were deﬁned as NeuN-PE(+) events, the threshold
being set by manual inspection and varying little between individual
runs. These cells were further gated to exclude events with high
side scatter-height, which were found in preliminary experiments
to emit high levels of background ﬂuorescence and compromise
sorted-cell purity. Individual neuronal subtypes, somatostatin(+) and
parvalbumin(+), were sorted in separate runs. Subtype-speciﬁc gates
were deﬁned to compensate for the increase in 647-heightwhich corre-
lateswith side scatter-area, as seen in Figs. 8–9. The shape of these gates
was drawn to include events which clearly lie above the background
level of ﬂuorescence, apparent from the inspection of the 647-height in-
tensity of DAPI(−) events. Somatostatin(−) and parvalbumin(−)
events were gated to include NeuN(+) events that were within back-
ground levels of light intensitywith respect to 647-height and side-scat-
ter area (~80%), to exclude highly andmoderately labeled somatostatin
and parvalbumin neurons. Within each subtype, cFos(+) and cFos(−)
populations were also gated. cFos(+) gates were set to include the
highest 5% c-Fos-488-height events for subtype(−) cells, and highest
10% for subtype(+) cells. cFos(−) gates were set to include the bottom
75% cFos-488-height events for both subtype(+) and subtype(−) cells.
It may be noted that cFos-488-height levels do not vary signiﬁcantly
with scatter, as this is a nuclear stain and nuclei size is relatively con-
stant in neurons.
2.6. RNA Extraction
Tubes containing sorted cell populations were centrifuged at
13,000 g and the supernatant was removed before freezing at−80 °C
until RNA extraction. RNA extraction was performed with Trizol, ac-
cording to manufacturer's directions with modiﬁcations. Following
Method A, cells were vortexed with 100 μl Of Trizol, phase separated
with 5 μl of bromo-anisole, and spun at 13,000 g for 15 min. The super-
natant was added to 50 μl of isopropanol with 1 μg of glycogen to aid in
pellet formation, spun 13,000 g for 6min, andwashedwith 75% ethanol.
Pellets were resuspended in 10 μl nuclease-free water. FollowingMethod B, cells were incubated overnight in 70 μl of RNA extraction
buffer at 60 °C for 16 h. RNA extraction buffer consists of 15 mM Tris–
HCL, pH = 8.0, 1% SDS, and 4 mg/ml Proteinase K. This solution was
then extracted with 150 μl TRIzol as above, with all other reactants
scaled up accordingly.
2.7. RTQPCR
First strand cDNA was synthesized using the ImPromp-II kit from
Promega (Madison, WI) using all RNA extracted from each sample. For
the quantitative RT-PCR (QPCR) experiments, the Universal
ProbeLibrary system from Roche (Indianapolis, IN) was used to design
primer/probe pairs. Primers were synthesized by IDT (Coralville, IA).
Primer sequences can be found in Supplementary Fig. S3. Duplicate am-
pliﬁcation reactionswere performed on a Roche 480 LightCycler II using
the Roche Light Cycler Master Mix following the manufacturer's direc-
tions. Ampliﬁcation of gapdh, a housekeeping gene, was performed si-
multaneously in every well to normalize ampliﬁcation thresholds to
input cDNA quantity. Relative expression for each gene of interest
(GOI) was determined by subtracting the gapdh ampliﬁcation threshold
from the GOI threshold for each sample well, using the point of 2nd de-
rivative maximum, as estimated by the Roche software package. It
should be noted when interpreting data that different sorted groups of
cells may have varied levels of gapdh/total mRNA as these cells are not
composed of the same cell-types. Statistical analyses of QPCR relative
expression data (# of cycles from gapdh ampliﬁcation) were performed
using a one-way analysis of variance (ANOVA) between compared
groups for each GOI. Tukey's multiple comparisons testing was used to
compare every possible pair of samples, and signiﬁcance levels were
set at p b 0.05. Bar graphs always display mean ± SEM.
2.8. Immunoﬂuorescence
Flash frozen brains were stored at−80 °C until processing. Coronal
sections (30 μm)were sliced on a cryostat and thawmounted onto per-
mafrost slides. These sliceswere immediately dipped into fresh 4%para-
formaldehyde in PBS for somatostatin and cFos staining, or 95% ethanol
for 5-HT2A, cFos, and Gad67 staining. The sectionswere ﬁxed for 45min
at room temperature and washed 3× in PBS before blocking for 30 min
in PBS with 2.5% donkey serum and 0.25% Triton. Sections were stained
on the slides for 2.5 h at room temperature, shaking in primary antibody
solution diluted in blocking buffer. The following antibodies were used:
rabbit-α-cFos 9F6 (1:300, Cell Signaling; RRID: AB_2247211), goat-α-
somatostatin D-20 (1:200, Santa Cruz; RRID: AB_2302603), mouse-α-
cFos C10 (1:200, Santa Cruz; RRID: AB_10610067), rabbit-α-5-HT2A
(1:150, Neuromics; RRID: AB_1612272), mouse-α-Gad67 MAB5406
(1:1000, Millipore; RRID: AB_2278725). Following primary incubation,
slides were washed 3× in PBS before incubating in the appropriate sec-
ondaries (1:500) for 1.5 h at room temperature. Slides were then
washed twice in PBS and coverslipped in mounting medium (Cytoseal
280). All antibodies that we used for FACS were also those we used in
subsequent immunoﬂuorescence experiments with brain slices (α-
cFos, α-phospho-cFos, α-somatostatin, α-parvalbumin, α-GFAP, α-
NeuN, α-5-HT2A, and α–Gad67). In every case for each antibody, (+)
cell populations sorted utilizing a particular antibody demonstrated
high expression of the mRNA for the gene encoding the protein target
of the antibody, with (−) sorted populations having little to no mRNA
expression for the same gene. Although gene expression levels often
correlate with protein expression levels, this is not always the case.
Therefore, some caution is warranted when interpreting this data with
regard antibody selectivity.
Slides used for quantitative analysis were viewed and imaged on a
Leica DMRA2 upright epiﬂuorescence microscope. Control and drug-
treated brains were processed together. Quantiﬁed images were ac-
quired with identical exposure settings, and displayed with identical
contrast/brightness settings. Quantiﬁcation of co-labeling was
266 D.A. Martin, C.D. Nichols / EBioMedicine 11 (2016) 262–277performed by two separate experimenters that were blinded to treat-
ment condition and their counts were averaged. Other images for pub-
licationwere acquired using a Zeiss epiﬂuorescencemicroscopewith an
Olympus DP-72 wide ﬁeld camera.
3. Results
3.1. Standard FACS Analysis of Cortical Cells
First, we slightly modiﬁed existing neurocytometric methodology
(Guez-Barber et al., 2012) to separate neurons from non-neurons, acti-
vated neurons from non-activated neurons, and astrocytes from other
non-neurons in themPFC and SSC. Our gating strategy for a representa-
tive sort and the appearance of sorted cells is shown in Fig. 1A–E. RT-
qPCR analysis validated the identity of cellular populations (Fig. 1F).
As expected, high levels of neuronal transcripts (grin1) relative to glial
transcripts (mag, slc1a2) were detected in neuronal compared to non-
neuronal populations. Higher levels of astrocyte-speciﬁc transcripts
(slc1a2), relative to oligodendrocyte transcripts (mag) were measured
in astrocyte compared to general non-neuronal populations (Fig. 1F).
In general, cortical neurons exhibit a continuum of phospho-cFos
(Ser32) expression (Fig. 2A). The psychedelic phenethylamine (R)-DOI
(6.0mg/kg, i.p.) induces phospho-cFos expression only in a small subset
of cells, visible as an increase in the number of neurons exhibiting high
levels of phospho-cFos IR in (R)-DOI treated rats compared to control
rats (Fig. 2C). This differential distribution was present in all compari-
sons (N = 5/region) of (R)-DOI treated and control neurons. For both
































Fig. 2. Gating and IEG expression of Fos(+) and Fos(−) neurons: A) Representative FACS st
cells within gates. B) Histogram overlay of mPFC neurons from (R)-DOI (red) and control (blue
IEG expression from SSC. “*”, “**”, “***”, and “ns” indicate p b 0.05, p b 0.01, p b 0.001, and non-
(N= 4–5/group). Only selected comparisons are shown.2.5% of phospho-cFos IR neurons and “Fos(−)” neurons as the lowest
80% of phospho-cFos IR neurons (Fig. 2A).
3.2. IEG Expression in Psychedelic-Activated Neurons
IEG expression is signiﬁcantly higher in DOI-Fos(+) neurons than
DOI-Fos(−) neurons for each IEG and brain region tested (Fig. 2B, D).
Control brains also contained activated neurons with higher levels of
IEGs in Con-Fos(+) compared to Con-Fos(−) groups for each brain re-
gion and IEG tested (Fig. 2B, D). DOI-Fos(+) cells had higher levels of
cfos, fosb, and egr2 expression compared to Con-Fos(+) cells in SSC. In
mPFC, however, only fosb expression was signiﬁcantly higher in DOI-
Fos(+) than Control-Fos(+) cells (Fig. 2A, B). DOI-Fos(−) neurons gen-
erally exhibited similar levels of IEG expression relative to Control-
Fos(−). Interestingly, egr2 expression was increased between DOI-
Fos(−) neurons relative to Con-Fos(−) neurons in the mPFC (Fig. 2B,
D). Two IEGs (cfos, fosb) were measured in unsorted, dissociated brain
tissue, and signiﬁcant increases were found in the treated group, as ex-
pected (Fig. S1). Together, these data indicate that the expression of
IEGs induced by (R)-DOI when measured in unsorted brain tissue is
mostly due to transcriptional activation of a small subset of neurons.
However, another subset of neurons in the mPFC appears to express
egr2, but not high levels of phospho-cFos, in response to (R)-DOI.
3.3. Activated Neurons Express Higher Levels of htr2a mRNA
Analysis of theDOI-Fos(+) activated population of neurons revealed
that they have signiﬁcantly highermRNA expression of 5-HT2A receptorIEG Expression - mPFC
IEG Expression - SSC
Gene
Gene
rategy for control and (R)-DOI treated neurons shown. Numbers represent percentages of
) animals with respect to phospho-cFos IR. C) IEG expression in sorted cells frommPFC. D)









































Fig. 3. GPCR gene expression inmPFC and SSC: A) htr2a levels in sorted cells. B) grm2 levels in sorted cells. C) htr2c levels in sorted cells D) htr1a levels in sorted cells. “*”, “**”, “***”, and
“ns” indicate p b 0.05, p b 0.01, p b 0.001, and non-signiﬁcant, respectively. One-way ANOVA, Tukey post-hoc performed between all groups (N= 4–5/group). Only selected comparisons
are shown.
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gions, implying a direct action of (R)-DOI on these neurons to activate
IEG expression (Fig. 3A). By contrast, no enrichment of htr2A transcripts
was found in Control-Fos(+) neurons relative to Control-Fos(−) neu-
rons. To rule out the possibility that (R)-DOI may cause an increase in
htr2A expression in Fos(+) cells, the levels of htr2A mRNA were mea-
sured in unsorted tissue and nodifference between treated and untreat-
ed samples was found (Fig. S1). Therefore, drug-activated neurons
contain higher levels of htr2AmRNA prior to drug administration. The
metabotropic glutamate receptor 2 (mGluR2; grm2) has been previous-
ly demonstrated to functionally interact with the 5-HT2A receptor
(Benneyworth et al., 2007; Gewirtz and Marek, 2000; Marek et al.,
2000). We found that grm2 mRNA is more abundant in DOI-Fos(+)
neurons compared to DOI-Fos(−) neurons in both the SSC and mPFC.
However, this pattern was also true of Control-Fos(+) and Control-
Fos(−) neurons in the mPFC (Fig. 3B). Therefore, DOI-Fos(+) neurons
that respond to DOI are enriched in grm2 transcripts relative to Con-
trol-Fos(+) neurons only in the SSC.
5-HT2C receptormRNA expression is not higher in (R)-DOI-activated
neurons, even though (R)-DOI has high afﬁnity for this receptor (Fig.
3C). We also found a signiﬁcant decrease in 5-HT1A receptor mRNA
levels in DOI-Fos(+) neurons relative to DOI-Fos(−) neurons and to
Control-Fos(+) neurons in the SSC, but not mPFC (Fig. 3D).
3.4. GABAergic Interneurons are Enriched in Activated Neurons
Because the neuronal population is comprised of both excitatory and
inhibitory neurons, we examined for enrichment of GABAergic inhibito-
ry neurons in the (R)-DOI activated population. In Control-Fos(+) neu-
rons of themPFC and SSC, very few transcripts speciﬁc for interneurons
(gad67, slc6a1) were present relative to Control-Fos(−) neurons, indi-
cating that few interneuronsproducephospho-cFos under baseline con-
ditions (Fig. 4A, B). DOI-Fos(+) neurons of themPFC and SSC, however,
contained levels of gad67 and slc6a1 that were comparable to DOI-
Fos(−) neurons, and much higher than Control-Fos(+) neurons (Fig.4A, B). To rule out the possibility that some neurons produced more
cell-type speciﬁc transcripts in response to (R)-DOI, gad67 levels were
measured in unsorted tissue and no difference was detected between
treated and control conditions (Fig. S1). These data indicate that
GABAergic interneurons are activated by (R)-DOI, consistentwith previ-
ous reports (Abi-Saab et al., 1999; Wischhof and Koch, 2012). Also,
levels of the excitatory cell marker slc17a7 (Vglut1) were measured
and no signiﬁcant difference in expression levels between any group
was found. Interestingly, DOI-Fos(+) neurons contained more slc17a6
(Vglut2) mRNA than DOI-Fos(−) neurons in the SSC, a pattern absent
in controls (Fig. 4B). Therefore, a subset of cells in SSC that express
VGlut2 is likely preferentially activated by (R)-DOI.
To determinewhich of themany subtypes of GABAergic cells are re-
cruited by (R)-DOI,we examined levels of several interneuron-subtype-
speciﬁc genes (sst, pvlb, calb2, htr3a) in sorted cell populations. These
markers are produced in largely mutually exclusive interneuron sub-
types, that together account for nearly all inhibitory neurons (Kubota
and Kawaguchi, 1994; Rudy et al., 2011). We either failed to detect or
detected only exceedingly low amounts of calb2 and htra3 mRNA in
Fos(+) samples from both the treated and control groups (not
shown), indicating that calretenin and 5-HT3 expressing GABAergic
cells are not the interneurons recruited by (R)-DOI. However, we
found a large and signiﬁcant increase in pvlbmRNA in DOI-Fos(+) com-
pared to Con-Fos(+) neurons in bothmPFC and SSC (Fig. 4A, B), and an
increase in sst mRNA in DOI-Fos(+) neurons relative to Con-Fos(+)
neurons only in SSC (Fig. 4B). No changes in sst mRNA were detected
in unsorted tissues (Fig. S1), indicating that (R)-DOI does not alter levels
of this gene. These data suggest that subsets of parvalbumin and so-
matostatin interneurons respond to (R)-DOI, but that the response dif-
fers by brain region.
3.5. Psychedelics Activate Non-neuronal Cells
The sorted non-neuronal populations from the SSC and mPFC (Fig.
1) are comprised of multiple cell types. As a heterogeneous group, we
Gene
Gene
Cell-type specific expression in SSC





















Fig. 4. Cell-type marker gene expression in mPFC and SSC: Levels of cell-type speciﬁc marker genes in mPFC (A) and SSC (B) in sorted cells. “*”, “**”, “***”, and “ns” indicate p b 0.05,
p b 0.01, p b 0.001, and non-signiﬁcant, respectively. One-way ANOVA, Tukey post-hoc performed between all groups (N = 4–5/group). Only selected comparisons are shown.
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trol non-neurons (Fig. S2). This result led us to hypothesize that (R)-DOI
also affects glia and astrocytes. Astrocyte populations were sorted from
other non-neurons by using an antibody directed against GFAP, an as-
trocyte marker. Astrocytes were found to be transcriptionally activated
by (R)-DOI, and in treated samples of both SSC andmPFC, astrocytes had
higher expression levels of cfos (Fig. S2). DOI-activated astrocytes also
had higher levels of per1 relative to Control-astrocytes in the mPFC
and SSC (Fig. S2).
3.6. Immunohistochemistry Validation of Gene Expression and FACS Results
We performed immunohistochemistry and immunoﬂuorescence
experiments to validate our FACS and gene expression analyses results,
and to locate cell-type speciﬁc activated cells in the cortex. In (R)-DOI-
treated animals, we observed cFos-immunoreactivity (IR) increasesthat were clearly localized to a densely stained band in layer Va imme-
diately below granular layer IV in the SSC, a wider, moderately stained
area in deep layer V, and a distinct thin layer along the subplate, just su-
perﬁcial to the white matter (Fig. S3), consistent with previous reports
(Leslie et al., 1993; Mackowiak et al., 1999; Scruggs et al., 2000;
Tilakaratne and Friedman, 1996). We also observed cFos(+) neurons
in high density throughout the deep mPFC, claustrum, insular, and
endopiriform cortex, and scattered in superﬁcial layers I-III throughout
the mPFC and SSC (Fig. S4B).
To conﬁrm that somatostatin-containing neurons are activated by
(R)-DOI, co-staining for cFos and somatostatin (SOM) was performed.
Double labeled cells were scattered throughout the cortex from theme-
dial to lateral areas, and in layers II-VI. This co-expression was quanti-
ﬁed in the agranular motor cortex and in the primary SSC from the
pial surface to the white matter (Fig. 5). Whereas very few SOM(+)
neurons produce appreciable cFos-IR under control conditions in the
C) D)
Somatostatin and cFos Colocalization










Fig. 5. Somatostatin and cFos quantiﬁcation: Co-labeling for cFos and somatostatin in two brain regionswasmeasured. A) Illustration indicating regions of quantiﬁcation inmotor cortex
and SSC. B) Representative images (63×) of SOM(+) cells from control (top), and (R)-DOI (bottom) sections. C) Average counts of SOM(+) cells/region are shown. D.) Average counts of
double-labeled SOM(+)/cFos(+) cells are shown. “*” and “ns” represent p b 0.05 and non-signiﬁcant. Student's t-test, N = 3 animals/group; counts from at least 3 slices/animal were
averaged per N.
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administration produces a robust induction of cFos-IR in SOM(+) cells
of the motor cortex and SSC (13.0% and 9.4%, respectively) (Fig. 5).
These results support the FACS data, and show that (R)-DOI activated
SOM(+) interneurons are scattered throughout the parietal cortex.
3.7. (R)-DOI Produces 5-HT2A Receptor Internalization
We used a speciﬁc and well characterized rabbit polyclonal 5-HT2A
antibody (Magalhaes et al., 2010; Weber and Andrade, 2010) to deter-
mine if there was a small population of cFos positive neurons that also
expressed 5-HT2A receptor protein. In control animals, 5-HT2A IR dis-
plays a characteristic, diffuse banding pattern seen in previous studies
withmice (Weber and Andrade, 2010), indicating expression is primar-
ily on neuronal processes rather than soma (Fig. 6A, C, E). As such, cFos
localization to 5-HT2A neurons was difﬁcult to ascertain in cortex from
control animals, as has been noted previously in mice (Weber and
Andrade, 2010). Nevertheless, strong immunoreactivity within a band
across layer V throughout frontal and parietal areas, and moderate im-
munoreactivity in layers I-III, deep layer V, and along the subplate was
observed in controls.
Interestingly, 5-HT2A IR following (R)-DOI administration exhibited
a very different pattern, clearly staining the peri-nuclear region andproximal processes of many cells throughout the cortex. These 5-HT2A
receptor expressing cells were located in the areas of non-localizable
staining present in the control brains (Fig. 6B, D, F), especially in deep
layer V and along the cortical subplate (Fig. S4). Additional 5-HT2A-la-
beled soma were located in layer Va, where 5-HT2A IR is most apparent
in controls, although much staining in this region remains diffuse fol-
lowing (R)-DOI administration (Fig. S4). Superﬁcial layer I-III neurons
were also labeled in some areas of the motor and somatosensory corti-
ces (Fig. 7, Fig. S5). We also observed that many neurons in lateral re-
gions of the brain, including the orbital cortex, insula, endopiriform
cortex, and claustrum, exhibited dramatic receptor redistribution,
wherein neuronal somata and proximal processes can be clearly distin-
guished as containing 5-HT2A IR in treated animals, but not controls (Fig.
6). The majority of clearly labeled 5-HT2A-containing cells did not ex-
press high levels of Gad67-IR (Fig. 6F), although a small subset of cells,
primarily in layer V of the motor cortex and SSC, as well as in the
endopiriform cortex, was found to co-express both proteins.
This (R)-DOI induced 5-HT2A receptor internalization allows for
analysis of colocalization of cFos and 5-HT2A IR in treated animals. In-
deed, cFos was induced in a small fraction of 5-HT2A neurons in each
of the regions where 5-HT2A IR was observed, consistent with our
FACS data. Colocalization was most extensive along the subplate, in
deep layer V, in layer Va, and in the claustrum (Fig. S4). Frontal cortical
C)  Control 5-HT2A D)  DOI 5-HT2A
E) F)
A) B)Control 5-HT2A DOI 5-HT2A
Control Gad67 and 5-HT2A DOI Gad67 and 5-HT2A
Fig. 6. (R)-DOI induces 5-HT2A receptor internalization within 5-HT2A(+) cells: A,B) 40× view of 5-HT2A-IR of deep layer V in prelimbic cortex of control (A) and treated (B) sections.
C,D) 10× view of 5-HT2A-IR in the lateral orbital cortex and agranular insular cortex (+4.2 mm from bregma) is shown in control (C) and treated (D) sections. E,F) 10× view of orbital
cortex showing overlay of 5-HT2A-IR (red) and Gad67-IR (green) in control (E) and treated (F) sections.
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and did not produce cFos in response to (R)-DOI (Fig. 7). Superﬁcial 5-
HT2A(+) neurons in the motor cortex (Fig. 7D–G) and the SSC were
also co-labeled with cFos. Interestingly, although many cells bind (R)-
DOI and respond by internalizing 5-HT2A receptors, only a fraction of
these cells respond by producing cFos. Further, many cells that do not
exhibit apparent 5-HT2A IR do express cFos in response to (R)-DOI
(i.e., Fig. 7).3.8. New FACS Methodology Permits Cell-Type Speciﬁc Sorting
Our initial FACS experiments demonstrate that subsets of a variety of
cell types are transcriptionally activated by (R)-DOI, including 5-HT2A,
somatostatin, and parvalbumin expressing neurons. However, most
neurons of these classes remain transcriptionally quiescent upon psy-
chedelic administration. Isolation of speciﬁc neuronal populations
would permit queries concerning molecular differences between
A)
 DOI-Treated 5-HT2A B)  DOI-Treated cFos






DOI cFos & 5-HT2A Overlay
Fig. 7. (R)-DOI induces cFos in some 5-HT2A(+) neurons: A,B,C) 20× view of deep PFC (+4.2mm from bregma) from treated rat, showing 5-HT2A-IR (A), cFos-IR (B), and the overlay of
both stains (C). Arrows mark double-labeled cells. D,E,F) 20× view of superﬁcial motor cortex (+2.7 mm from bregma) from treated rat, showing 5-HT2A-IR (D), cFos-IR (E), and the
overlay of both stains (F). Arrows mark double-labeled cells.
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ously described FACS methods (Guez-Barber et al., 2012), akin to our
Method A, isolate neurons from initially unﬁxed brains. These methods
result in small cell bodies composed primarily of a nucleus and depleted
of all processes and most of the cytoplasm (see Fig. 1). In our hands, we
found that staining for cytoplasmic and extracellular proteins including
parvalbumin, somatostatin, Gad67, and 5-HT2A was not possible in
these preparations. Therefore, we developed methodology to prepare
neurons for FACS that ﬁxes proteins prior to dissociation, but still allows
for dissociation and downstream RNA analysis (Experimental Proce-
dures, Method B). Microscopic analysis of these cells demonstrates
that sorted neurons retain soluble cytosolic proteins, including
parvalbumin and somatostatin (Fig. 10).
Initially, SOM cells were puriﬁed with FACS using Method B on SSC
from fresh, immersion-ﬁxed tissue obtained from treated and control
animals (N= 4/group) (Fig. 8). Sorted SOM(+) neurons under control
conditions exhibited very little cFos-IR, whereas a marked induction
was apparent in a subset of SOM(+) neurons from animals treated
with (R)-DOI (Fig. 8). We segregated 4 groups of neurons for sortingfrom the (R)-DOI group: DOI-SOM(+)/cFos(+); DOI-SOM(+)/cFos(−
); DOI-SOM(−)/cFos(+); DOI-SOM(−)/cFos(−). We did not sort
SOM(+)/cFos(+) neurons in controls as this population was exceed-
ingly small. Therefore, three neuronal groupswere sorted from the con-
trol group: CON-SOM(+); CON-SOM(−)/cFos(+); CON-SOM(−)/
cFos(−) (Fig. 8). To determine the purity of neurons sorted with our
FACS strategy, we measured the levels of sst, slc17a7, and cfos in each
of the 7 sorted populations (Fig. 11; Table 1). QPCR analysis veriﬁed
that all SOM(+) populations were highly enriched in sst and depleted
in slc17a7 when compared to SOM(−) populations, in both control
and (R)-DOI groups (Fig. 11; Table 1). We also found that DOI-
SOM(+)/cFos(+) neurons contained high levels of cfos mRNA equal
to DOI-SOM(−)/cFos(+) neurons, and signiﬁcantly more than all
other populations (Fig. 8, Table S1). Conversely, DOI-SOM(+)/cFos(−)
neurons have low levels of cfos similar to Control-SOM(+) neurons
(Fig. 11). These results indicate that (R)-DOI highly transcriptionally ac-
tivates a subset of SOM(+) neurons, whereas the majority remain qui-
escent. Comparison of SOM(+)/cFos(+) cells to SOM(+)/Fos(−) cells
revealed that activated and non-activated somatostatin neurons
SOM(+) Fos-IR
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Fig. 8. FACS gating for SSC Somatostatin neurons: Data are from a representative sort; all runs produced similar patterns. Numbers represent percentages of cells within gates. A) All
events are shown. DAPI(+) gate includes cells and excludes debris. B) NeuN-PE-Height/SideScatter-Height gate eliminates non-neurons and irregularly-shaped DAPI(+) events. C)
Neurons are gated on Somatostatin-647-Height to select SOM(+) and SOM(−) neurons. D) 3 Control groups are gated: SOM(+), SOM(−)/Fos(+), and SOM(−)/Fos(−). E) 4 treated
groups are gated: SOM(+)/Fos(+), SOM(+)/Fos(−), SOM(−)/Fos(+), SOM(−)/Fos(−). F) Histogram of cFos-immunoreactivity for all SOM(+) neurons from (R)-DOI (red) and
control (blue) tissues.
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this tomean that SOM(+) neurons are primarily indirectly activated by
(R)-DOI.
We also examined parvalbumin expressing neurons, which have
been reported to express EGFP in htr2a-EGFP mice (Weber and
Andrade, 2010). The gating strategy for sorting parvalbumin(+)
(PV(+))neurons is analogous to that used for sorting SOM(+)neurons,
(Fig. 9). As expected from our earlier FACS studies, PV(+) neurons in
the mPFC contain little cFos-IR under control conditions, whereas a sig-
niﬁcant fraction becomehighly activated in response to (R)-DOI (Fig. 9).
We veriﬁed that sorted populations were pure, as all groups of PV(+)
neurons displayed high levels of pvlb and low levels of slc17a7 relative
to PV(−) neurons (Fig. 11; Table 1). We also conﬁrmed that DOI-
PV(+)/cFos(+) neurons contained very high levels of cfos mRNA,Table 1
Summary of cell-type speciﬁc marker gene expression: All samples of sorted cells from
a particular neuronal subtype PV(+), PV(−), SOM(+), and SOM(−), were grouped to-
gether and gene expression levels are shown for select genes. Numbers represent percent-
age changes (±SEM) relative to PV(−) (top 2 rows) or SOM(−) (bottom 2 rows), using
gapdh to normalize. PV(+), SOM(+), N = 12; PV(−), SOM(−), N = 16. Students t-test,
“***” indicates p b 0.001.
Sst Slc17a7 Htr2a
All SOM(+) 4382 ± 590%*** 6.09 ± 1.72%*** 26.7 ± 8.6%***
All SOM(−) 100 ± 18.3% 100 ± 7.9% 100 ± 10.6%
Pvlb Slc17a7 Htr2a
All PV(+) 3401 ± 801%*** 6.04 ± 1.27%*** 140 ± 29.0% (ns)
All PV(−) 100 ± 43.7% 100 ± 10.22% 100 ± 12.4%equivalent to DOI-PV(−)/−cFos(+) neurons, and higher than every
other group (Fig. 11). Conversely, DOI-PV(+)/cFos(−) neurons have
low levels of fos, similar to CON-PV(+) neurons (Fig. 11). These results
support our FACS analysis (Fig. 9F), which shows that a subset of PV(+)
neurons become activated by (R)-DOI, while themajority remain quies-
cent. Comparing activated PV(+) neurons to non-activated neurons
within the (R)-DOI group, we did not observe a statistically signiﬁcant
increase in htr2a expression (Fig. S6), although PV(+) neurons express
htr2a at a level similar to or higher than that seen in PV(−) populations
(Fig. S7, Table 1). These results suggest that direct binding to and activa-
tion of PV(+) neurons by (R)-DOImay not be a critical factor in their ac-
tivation, consistentwith a primarily indirectmechanism of activation of
PV(+) neurons by psychedelics.
3.9. IEG Induction Varies across Cell Types
Although levels of cfos induction among SOM(+) and PV(+) neu-
rons that were cFos(+) were similar to levels of cfos induction in acti-
vated SOM(−) and PV(−) neurons following (R)-DOI, we asked
whether other IEGs might exhibit cell-type speciﬁc activation patterns.
Interestingly, we found that all groups of sorted SOM(+) interneurons
display similar levels of egr2, regardless of their activation state, where-
as PV(+) interneurons never contained egr2, regardless of activation
state (Fig. 11). Within PV(−) and SOM(−) populations, the expected
pattern of egr2 induction wasmeasured between activated and non-ac-
tivated neurons, based on our initial FACS and QPCR studies (Fig. 11).
These results demonstrate that heterogeneous transcriptional re-
sponses occur between different neuronal types following psychedelic
administration, despite similar induction of cFos protein and fosmRNA.
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Fig. 9. FACS gating for mPFC Parvalbumin neurons: Data are from a representative sort; all runs produced similar patterns. Numbers represent percentages of cells within gates. A) All
events are shown. DAPI(+) gate includes cells and excludes debris. B) NeuN-PE-Height/SideScatter-Height gate eliminates non-neurons and irregularly-shaped DAPI(+) events. C)
Neurons are gated on Parvalbumin-647-Height to select PV(+) and PV(−) neurons. D) 3 Control groups are gated: PV(+), PV(−)/Fos(+), and PV(−)/Fos(−). E) 4 treated groups are
gated: PV(+)/Fos(+), PV(+)/Fos(−), PV(−)/Fos(+), PV(−)/Fos(−). F) Histogram of cFos-immunoreactivity for all PV(+) neurons from (R)-DOI (red) and control (blue) tissues.
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Our results indicate that (R)-DOI transcriptionally activates hetero-
geneous populations of inhibitory and excitatory cells in both mPFC
and SSC. The activated excitatory neuronal cell populations express
higher levels of 5-HT2A receptor mRNA in mPFC, and higher levels of
both 5-HT2A and mGluR2 receptor mRNA in SSC. Neurons containing
the highest levels of phosphorylated (Ser32) cFos express levels of
htr2a approximately 3–4 times that of (Ser32) cFos positive neurons
of the control treatment group. We conﬁrmed with immunoﬂuores-
cence microscopy that a small subset of 5-HT2A receptor-expressing
neurons produces cFos in response to (R)-DOI in the mPFC, SSC, orbital
cortex, and claustrum. Although this result might be anticipated be-
cause 5-HT2A receptor activation is necessary for psychedelic-induced
responses, several previous studies have each failed to co-localize cFos
to 5-HT2A-IR cells (Mackowiak et al., 1999; Pei et al., 2004; Scruggs et
al., 2000). One potential explanation is that these studies used a 5-
HT2A receptor monoclonal antibody from Pharmingen that is no longer
available. By contrast, one study has shown cFos induction within 5-
HT2A cells of the SSC following DOI, using a different antibody
(ab16028, Abcam, discontinued)(Hazama et al., 2014). Neither of
these two receptor antibodies, however, has been extensively veriﬁed
for speciﬁcity in htr2a knockout animals, whereas the antibody we
employed in our studies has been validated (Magalhaes et al., 2010;
Weber and Andrade, 2010).
We hypothesize that the small population of excitatory neurons ex-
pressing increased levels of htr2AmRNA that are directly activated by
(R)-DOI represent a “trigger population”, and are neurons that depolar-
ize upon exposure to psychedelics. Further, we propose that activationof these neurons initiates the events leading to recurrent activity, corti-
cal network destabilization, and the host of perceptual and cognitive be-
haviors associated with psychedelics. Our results indicate that a large
number of 5-HT2A-expressing cells undergo dramatic receptor redistri-
bution to the soma following (R)-DOI in all frontal areas that normally
express 5-HT2A receptors, and we have also observed this phenomena
following LSD (unpublished observations). These results are consistent
with agonist-induced receptor internalization,whichhas been observed
previously for the 5-HT2A receptor in vitro (Berry et al., 1996; Karaki et
al., 2014). Interestingly, manyneurons that internalize 5-HT2A receptors
upon (R)-DOI administration do not express cFos. Furthermore, most
neurons that produce cFos in response to (R)-DOI do not express appre-
ciable levels of 5-HT2A receptors. Future studies are necessary to deter-
mine the differences between 5-HT2A-expressing cells that do and do
not become activated by psychedelics.
The data we present here are from animals treated with a singular,
high dose of (R)-DOI. We chose a dose that was likely to produce near
maximum increases in cFos induction (Leslie et al., 1993) in order to
produce robust signals for our FACS separations and downstream
mRNA analyses. However, we note that despite the high dose given,
IEG induction is still primarily restricted to a relatively small group of
highly activated neurons. Also, while (R)-DOI does have afﬁnity for
the 5-HT2C receptors, which modiﬁes its effects on behavior, we did
not ﬁnd that htr2c levelswere differentially distributed between treated
animals and controls with respect to activated and non-activated neu-
rons, in contrast to enriched htr2a levels in (R)-DOI activated cells. Fur-
thermore, we have observed in preliminary experiments a similar
induction of cFos in 5-HT2A-expressing cells following LSD (0.5 mg/kg,

































Fig. 10. Images of sorted interneurons: Panel shows representative images of cells sorted using Method B, viewed at 60×. Filters used include brightﬁeld (left), DAPI (center), and 647
(right). Cells include unsorted, dissociated tissue, including cells and debris (top row), sorted PV(−) neurons (2nd row), sorted PV(+) neurons (3rd row), and sorted SOM(+) neurons
(4th row). Note that sorted cells contain occasional PV(+) neurons and sorted cells retain cytoplasmic proteins.
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ing proﬁles, at a variety of doses to generalize the responses observed
here.Fig. 11. QPCRanalysis of sorted interneurons:A)High levels of sst are found in SOM(+) cells, b
Low levels of slc17a7 are found in SOM(+) cells relative to SOM(−) cells. D) Low levels of slc17
levels of fos. F) DOI-PV(+)/Fos(+) cells have high levels of fos. G) DOI-SOM(+)/Fos(+) cells h
cells. In each panel, one-way ANOVA & Tukey post-hoc test was performed between all groups
illustrated here for clarity. Symbols “*”, “**”, and “***” indicate p b 0.05, p b 0.01, and p b 0.001The primary inhibitory interneuron populations activated by (R)-
DOI are the somatostatin and parvalbumin neurons. For both types of
interneurons, only a small subset of the total number of interneuronsut not SOM(−) cells. B)High levels of pvlb are found in PV(+) cells but not PV(−) cells. C)
a7 are found in PV(+) cells relative to PV(−) cells. E) DOI-SOM(+)/Fos(+) cells have high
ave levels of egr2 similar to DOI-SOM(+)/Fos(−) cells. H) Egr2 is not expressed in PV(+)
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276 D.A. Martin, C.D. Nichols / EBioMedicine 11 (2016) 262–277are activated. One hypothesis is that interneurons, a subset of which ex-
press 5-HT2A receptors, are directly bound and activated by psyche-
delics, as demonstrated in slices (Weber and Andrade, 2010; Zhou and
Hablitz, 1999). In our studies we did not ﬁnd a substantial enrichment
of htr2a in activated interneurons relative to non-activated interneu-
rons. Also, co-staining between Gad67-IR and 5-HT2A-IR showed that
the majority of clearly labeled 5-HT2A(+) cells in the drug-treated con-
dition were excitatory, although deep layers of the parietal cortex occa-
sionally contained double-labeled cells, and PV(+) cells do express
htr2a. While these data do not preclude the possibility that some inter-
neurons are modulated by direct actions of (R)-DOI, they indicate that
interneuron activation by psychedelics is probably indirect, and in re-
sponse to increases in cortical neural activity. Interestingly, activated so-
matostatin interneurons do not produce egr2 in response to (R)-DOI,
and parvalbumin interneurons do not produce egr2 in either baseline
or activated states. Egr2 induction in the cortex has been proposed to
be a marker for psychedelic activation of 5-HT2A receptors (Gonzalez-
Maeso et al., 2003). Our results indicate that egr2 induction is restricted
to particular cell types in response to psychedelics, and is not a generally
induced marker. Further studies will be required to examinemore fully
the nature of cell-type speciﬁc IEG induction and the importance of
these effects for effecting long-term cellular changes.
The functional consequences of interneuron activation with respect
to psychedelic-induced behaviors are likely important, and this area re-
mains unexplored. Psychedelicsmarkedly affect the local ﬁeld potential
(LFP) in the gamma frequency range (Wood et al., 2012), which is large-
ly modulated by GABAergic cells. Neuronal oscillations are important in
coordinating information transfer throughout the brain and disruption
of these rhythms might be a critical component of the diverse effects
of psychedelics (Muthukumaraswamy et al., 2013). In our previous
studies of long-term LSD administration,we found a variety of GABA-re-
lated mRNA expression abnormalities weeks after drug administration
was halted, implicating persistent dysregulation (Martin et al., 2014).
Additionally, the consistent ﬁnding of GABA-related molecular changes
in the cortex of psychiatric patients (Gonzalez-Burgos and Lewis, 2008)
warrants additional investigations into the function of these cells in nor-
mal and abnormal states.
In addition to neuronal activation, subpopulations of non-neurons,
including astrocytes, respond to (R)-DOI by producing fos and per1.
Per1 is a core component of the circadian clock and its expression has
been shown to cycle in astrocytes (Prolo et al., 2005). Although global
brain per1 mRNA levels are known to increase in response to psyche-
delics (Gonzalez-Maeso et al., 2003), regulation of its, or any other
gene's, transcription by psychedelics in astrocytes has not been previ-
ously examined. The meaning and functional consequences of this re-
sponse are unknown, but the idea that astrocytes may be involved
with electrophysiological responses to psychedelics has been proposed
(Aghajanian, 2009). Astrocytes are also known to be extensively in-
volved in regulating metabolic substrate transport to neurons (Gandhi
et al., 2009), as well as blood ﬂow to local areas of the brain (Zonta et
al., 2003). Psychedelics are known to increase glucose utilization in
the cortex (Vollenweider et al., 1997), and cerebral glucose is primarily
removed from the blood by astrocytes. Interestingly, blood ﬂow and
BOLD responses in the cortex are decreased following psilocybin
(Carhart-Harris et al., 2012), leaving open questions surrounding
neurovascular coupling during the psychedelic state (Spain et al.,
2015). Activation of particular cell types, including astrocytes and inter-
neurons, may play separable roles in neurovascular responses.
In order to study neuronal subtype-speciﬁc drug effects, we devel-
oped FACS methods applicable for robust sorting of cortical cells based
on soluble cytosolic proteins that preserve RNA. Using thismethodology
we segregated and separately analyzed populations of both
parvalbumin and somatostatin interneurons for this study. We have
also validated this methodology to sort based upon extracellular mem-
brane proteins and in routinely ﬁxed human post-mortem brain (un-
published data). Populations of cells are likely N94% pure, as slc17a7 isreduced by this amount in both SOM(+) and PV(+) cells (Table 1).
Sort purity may be higher, because some slc17a7 expression is expected
in these cell types, as slc17a7 has been detected in interneurons by sin-
gle cell QPCR (Rossier et al., 2015). It should be noted that while mRNA
moieties present in the cytoplasm are preserved with this protocol, ge-
netic information located in the processes, such as dendrites and axons,
is not preserved as most processes are lost during the FACS procedures.
Signiﬁcantly, the ability to quickly separate large populations of
brain cells based on awide variety of soluble, cytosolic, and extracellular
membrane proteins and retain mRNA stability will expand the utility of
FACS in the neurosciences. Currently, to isolate highly enriched popula-
tions of cells based on cytosolic or extracellular membrane proteins re-
lies on the laborious and low throughput method of laser capture
microdissection. Neurocytometry can now be employed to isolate
large andmultiple populations of cells from a single block of brain tissue
to study cell-type speciﬁc transcriptional responses to drug administra-
tion, environmentalmanipulation, anddisease progression, and only re-
quires access to ﬂow cytometry infrastructure.
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